Compare the effect of probiotics "(Bifidobacterium Infantis, Lactobacillus Reuteri, Lactobacillus Rhamnosus)" and placebo in the treatment of infantile colic

Infantile colic is a benign and common disorder. The disease occurs in the first 3-4 months of age. The disease presents with strong crying and irritability. This study was a randomized double-blind placebo-controlled trial. In the study, 70 Infants aged 21 days to 4 months with Wessel criteria that referred to Bahrami Children’s Hospital in Tehran, were enrolled. The main inclusion criteria include: the infants with crying at least 3 hours a day; for at least 3 days a week; The main exclusion criteria include: the children with organic gastrointestinal disorders; consumption of any antibiotic, probiotics and formula containing probiotics and other madications for colic before entering the study; The infantiles were randomly divided in two groups (case and control groups). The first group (case group) was given probiotic from Bifidobacterium Infantis, Lactobacillus Reuteri, and Lactobacillus Rhamnosus strain (Pedilact® brand manufactured by Iranian company, Zist Takhmir) with dose 5 drops per day orally for 4 weeks. The second group (control group) received placebo for the same period. Patients were followed up on days 7, 21 and 30 after initiation of treatment. In the follow up period these items were recorded: duration of crying, number of crying attacks per day, crying day in week and drug side effects. The purpose of the study was to evaluate the effect of probiotics in treatment of infantile colic.

Vice Chancellor of Research, Tehran University of Medical Sciences